carnitine has been researched along with Kahler Disease in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lodi, A | 1 |
Tiziani, S | 1 |
Khanim, FL | 1 |
Günther, UL | 1 |
Viant, MR | 1 |
Morgan, GJ | 1 |
Bunce, CM | 1 |
Drayson, MT | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Prospective Long-term Observational Study in Patients With Monoclonal Gammopathy of Undetermined Significance[NCT05539079] | 2,000 participants (Anticipated) | Observational | 2023-09-06 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 other study available for carnitine and Kahler Disease
Article | Year |
---|---|
Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease.
Topics: Acetylcarnitine; Aged; Aged, 80 and over; Biomarkers, Tumor; Carnitine; Clinical Trials, Phase III a | 2013 |